-
公开(公告)号：US07754859B2
公开(公告)日：2010-07-13
申请号：US11833473
申请日：2007-08-03
申请人： Naomi Laing , Jaspal Singh Kang , Ian Foltz , Gadi Gazit-Bornstein , Xiao-Dang Yang , David Charles Blakey , Sue A. Cartlidge
发明人： Naomi Laing , Jaspal Singh Kang , Ian Foltz , Gadi Gazit-Bornstein , Xiao-Dang Yang , David Charles Blakey , Sue A. Cartlidge
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。
-
公开(公告)号：US08697664B2
公开(公告)日：2014-04-15
申请号：US12708022
申请日：2010-02-18
申请人： Naomi Laing , Jaspal Singh Kang , Ian Foltz , Gadi Gazit-Bornstein , Xiao-Dang Yang , Sue A. Cartlidge , David Charles Blakey
发明人： Naomi Laing , Jaspal Singh Kang , Ian Foltz , Gadi Gazit-Bornstein , Xiao-Dang Yang , Sue A. Cartlidge , David Charles Blakey
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。
-
3.发明申请公开(公告)号：US20090324601A1
公开(公告)日：2009-12-31
申请号：US12376052
申请日：2007-08-02
申请人： David Charles Blakey , Susan Ann Cartlidge , Ian Foltz , Jaspal Singh Kang , Laura Taylor , Gadi Gazit-Bornstein , Naomi Laing
发明人： David Charles Blakey , Susan Ann Cartlidge , Ian Foltz , Jaspal Singh Kang , Laura Taylor , Gadi Gazit-Bornstein , Naomi Laing
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。
-
4.发明申请公开(公告)号：US20080089837A1
公开(公告)日：2008-04-17
申请号：US11833473
申请日：2007-08-03
申请人： Naomi LAING , Jaspal Kang , Ian Foltz , Gadi Gazit-Bornstein , Xiao-Dang Yang , David Blakey , Sue Cartlidge
发明人： Naomi LAING , Jaspal Kang , Ian Foltz , Gadi Gazit-Bornstein , Xiao-Dang Yang , David Blakey , Sue Cartlidge
IPC分类号： A61K39/395 , A61K51/10 , C07K16/28 , C07K16/30 , C12N15/13 , C12N15/85 , C12N5/06 , C12P21/08
CPC分类号： C07K16/2863 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
摘要翻译： 本文公开了针对抗原PDGFR-α的靶向结合剂及其用途。 更具体地，本发明涉及针对抗原PDGFR-α的完全人单克隆抗体以及这些抗体的用途。 本发明的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所描述的靶向结合剂和抗体可用作诊断和治疗与PDGFR-α的活性和/或过度表达相关的疾病。
-
公开(公告)号：US07572444B2
公开(公告)日：2009-08-11
申请号：US11303608
申请日：2005-12-16
申请人： Ian Foltz , Chadwick King , Peter Koon Bong Ling , Jaspal Singh Kang , Kathy Manchulenko , Francine Chen , Caroline Darne Scatena , Bruce A. Keyt , Edwin Madison , Wayne R. Godfrey , Stanislaw K. Morkowski , Jennifer H. Richardson
发明人： Ian Foltz , Chadwick King , Peter Koon Bong Ling , Jaspal Singh Kang , Kathy Manchulenko , Francine Chen , Caroline Darne Scatena , Bruce A. Keyt , Edwin Madison , Wayne R. Godfrey , Stanislaw K. Morkowski , Jennifer H. Richardson
IPC分类号： A61K39/395 , A61K51/00 , C07H21/04 , C12N5/06 , C12P21/06
CPC分类号： C07K16/40 , C07K2317/732 , C07K2317/76 , C07K2317/92 , G01N33/57492 , G01N2500/04
摘要： Binding proteins, such as fully human monoclonal antibodies and fragments thereof, directed to the antigen Matriptase and uses of such binding proteins are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to Matriptase are also disclosed. The invention also discloses cell lines expressing such immunoglobulin molecules and monoclonal antibodies to Matriptase. The antibodies can be used to detect, prevent, and treat diseases such as cancer.
摘要翻译： 公开了涉及抗原Matriptase的结合蛋白，例如完全人单克隆抗体及其片段，以及这些结合蛋白的用途。 还公开了编码和包含能够结合Matriptase的重链和轻链免疫球蛋白分子的氨基酸序列的核苷酸序列。 本发明还公开了表达这种免疫球蛋白分子的细胞系和对Matriptase的单克隆抗体。 抗体可用于检测，预防和治疗诸如癌症的疾病。
-
公开(公告)号：US08350011B2
公开(公告)日：2013-01-08
申请号：US12376196
申请日：2007-08-02
IPC分类号： C07K16/30 , A61K39/395
CPC分类号： C07K16/40 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/32 , C07K2317/21 , C07K2317/33 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to ErbB2, preferably human ErbB2. In another embodiment, the antibodies or antigen-binding portions thereof inhibit ErbB2. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins or portions thereof derived from human anti-ErbB2 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-ErbB2 antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
摘要翻译： 本发明涉及特异性结合ErbB2，优选人ErbB2的人抗体及其抗原结合部分的抗体。 在另一个实施方案中，抗体或其抗原结合部分抑制ErbB2。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗ErbB2抗体的分离的重链和轻链免疫球蛋白或其部分和编码这种免疫球蛋白的核酸分子。 本发明还涉及使用抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗ErbB2抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物或植物。
-
公开(公告)号：US20120114667A1
公开(公告)日：2012-05-10
申请号：US13141564
申请日：2009-12-21
申请人： Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
发明人： Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
IPC分类号： A61K39/395 , C07K16/18 , C07H21/04 , C12N15/63 , C12N5/16 , C12P21/06 , A61P35/00 , C07K14/00 , A61K38/00 , A61P29/00 , A61P9/10 , A61P9/00 , A61P5/00 , C12N5/10 , C07K16/00
CPC分类号： C07K16/2842 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
摘要翻译： 本发明涉及针对α5和bgr的靶向结合剂及其用途。 更具体地，本发明涉及针对α5和bgr的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与α5和bgr1的活性和/或过度产生相关的疾病和作为诊断。
-
公开(公告)号：US20120107324A1
公开(公告)日：2012-05-03
申请号：US13141608
申请日：2009-12-21
申请人： Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
发明人： Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
IPC分类号： A61K39/395 , C07K14/435 , C07K16/00 , A61P35/00 , C12N15/62 , C12N5/10 , C12P21/08 , C07K5/08 , C07H21/04
CPC分类号： B01F5/0619 , B01F5/0613 , B01F5/0617 , B01F15/00935 , B01F2005/0639
摘要： The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
摘要翻译： 本发明涉及针对α5和bgr的靶向结合剂及其用途。 更具体地，本发明涉及针对α5和bgr的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与α5和bgr1的活性和/或过度产生相关的疾病和作为诊断。
-
公开(公告)号：US20140314784A1
公开(公告)日：2014-10-23
申请号：US14232751
申请日：2012-07-19
申请人： Vahe Bedian , Youzhen Wang , Ian Foltz , Palaniswami Rathanaswami , Jaspal Singh Kang , Adeela Kamal , Philipp Steiner
发明人： Vahe Bedian , Youzhen Wang , Ian Foltz , Palaniswami Rathanaswami , Jaspal Singh Kang , Adeela Kamal , Philipp Steiner
IPC分类号： C07K16/28 , A61K45/06 , A61K39/395
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.
摘要翻译： 本公开涉及特异性结合CXCR4并抑制CXCR4的生物学活性的抗体或抗原结合片段以及这些试剂的用途。 更具体地，本公开涉及针对CXCR4的完全人抗体或抗原结合片段，其特异性结合CXCR4和这些抗体的用途。 本公开的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所公开的抗体（包括抗原结合片段）可用作诊断和治疗与CXCR4的活性和/或表达相关的疾病。
-
公开(公告)号：US07728113B2
公开(公告)日：2010-06-01
申请号：US11894560
申请日：2007-08-20
申请人： Vahe Bedian , Madhav Narasimha Devalaraja , Ian Foltz , Mary Haak-Frendscho , Sirid-Aimée Kellermann , Joseph Edwin Low , James Leslie Mobley
发明人： Vahe Bedian , Madhav Narasimha Devalaraja , Ian Foltz , Mary Haak-Frendscho , Sirid-Aimée Kellermann , Joseph Edwin Low , James Leslie Mobley
CPC分类号： C07K16/243 , A61K38/193 , A61K39/395 , A61K2039/505 , C07K16/24 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G06Q30/02 , G06Q30/0601 , G06Q40/04 , G06Q50/12 , Y02A50/412
摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.
摘要翻译： 本发明涉及特异性结合M-CSF，优选人M-CSF的抗体及其抗原结合部分，其功能是抑制M-CSF。 本发明还涉及人抗M-CSF抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗M-CSF抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗M-CSF抗体的方法，包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗M-CSF抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物和转基因植物。
-
-
-
-
-
-
-
-
-
搜索结果
71 条记录 (耗时 0.086 秒)